Literature DB >> 31646586

Downregulation of linc00961 contributes to promote proliferation and inhibit apoptosis of vascular smooth muscle cell by sponging miR-367 in patients with coronary heart disease.

C-T Wu1, S Liu, M Tang.   

Abstract

OBJECTIVE: Atherosclerosis is one of the most important risk factors for coronary heart disease (CHD), and growing evidence has shown that long non-coding RNAs (lncRNAs) can serve as prospective markers for atherosclerosis. In this study, we mainly focused on the potential roles of linc00961 in CHD patients. PATIENTS AND METHODS: qRT-PCR was used to detect the expressions of linc00961 and miR-367 in CHD patients and ApoE-/-mice, and the correlations were analyzed. Then, HA-VAMC was respectively treated with 5 inflammatory factors and hypoxia conditions to explore the factors that affect linc00961 levels. Furthermore, the linc00961 overexpression lentivirus (LV-linc00961) and linc00961 downregulation lentivirus (LV-sh linc00961) were purchased and transfected into human vascular smooth muscle cells (VSMCs). CCK8 assay was carried out to measure the cell proliferation of VSMC, and the levels of Cyclin D1, Bcl-2, Bax, and cleaved caspase-3 were detected by RT-PCR and Western blot. Moreover, the Luciferase assay was performed to explore the binding site of linc00961 and miR-367. Finally, the miR-367 inhibitor was transfected into LV-sh linc00961 VSMCs to confirm the linc00961 functions via miR-367.
RESULTS: We found that linc00961 was significantly decreased in patients with CHD and ApoE-/-mice. Additionally, linc00961 was reduced in VSMCs at the conditions of hypoxia and C-reactive protein (CRP). Most importantly, the overexpression of linc00961 significantly inhibited the VSMCs proliferation, repressed the levels of Cyclin D1 and Bcl-2, and increased the levels of Bax and cleaved caspase-3. However, the downregulation of linc00961 promoted VSMCs proliferation, increased the levels of Cyclin D1 and Bcl-2, and repressed the levels of Bax and cleaved caspase-3. We also found that miR-367 was downregulated following the upregulation of linc00961, while it was upregulated following the downregulation of linc00961. The Luciferase gene reporter assay indicated that linc00961 could directly bind with miR-367 in VSMCs. Finally, we found that linc00961 could inhibit proliferation and promote apoptosis of VSMCs via binding with miR-367.
CONCLUSIONS: According to the results, our study revealed that linc00961 was significantly decreased in patients with CHD and ApoE-/-mice. Furthermore, our findings firstly uncovered that linc00961 was reduced by hypoxia and CRP in VSMCs. The downregulation of linc00961 contributed to promote proliferation and inhibit apoptosis of VSMCs by sponging miR-367 in CHD patients, which might provide a potential target for treating atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31646586     DOI: 10.26355/eurrev_201910_19168

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  Identifying the key microRNAs implicated in atrial fibrillation.

Authors:  Yuejuan Cao; Li Cui
Journal:  Anatol J Cardiol       Date:  2021-06       Impact factor: 1.596

2.  LncRNA LINC00961 regulates endothelial‑mesenchymal transition via the PTEN‑PI3K‑AKT pathway.

Authors:  Jin-Xing Hu; Ze-Qi Zheng; Ting Kang; Wei Qian; Shan-Hua Huang; Bin-Gong Li
Journal:  Mol Med Rep       Date:  2022-06-03       Impact factor: 3.423

3.  LINC00961 functions as an anti-oncogene in non-small cell lung carcinoma by regulation of miR-3127.

Authors:  Yong-Gang Liu; Jia Li; Fang Nie; Gao-Wa Jin
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

4.  The Influence of the LINC00961/SPAAR Locus Loss on Murine Development, Myocardial Dynamics, and Cardiac Response to Myocardial Infarction.

Authors:  Ana-Mishel Spiroski; Rachel Sanders; Marco Meloni; Ian R McCracken; Adrian Thomson; Mairi Brittan; Gillian A Gray; Andrew H Baker
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.